Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic

References

• SAMHSA. Key Substance Use and Mental Health Indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2019.
   Google Scholar
• Centers for Disease Control and Prevention. U.S. opioid prescribing rate maps. https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html. Published 2018. Accessed November 24, 2018.
   Google Scholar
• Bao Y, Pan Y, Taylor A, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35(6):1045–1051.
   PubMed Web of Science ®Google Scholar
• Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff (Millwood). 2017;36(4):733–741.
   PubMed Web of Science ®Google Scholar
• Leslie DL, Ba DM, Agbese E, Xing X, Liu G. The economic burden of the opioid epidemic on states: the case of Medicaid. Am J Manag Care. 2019;25(13 Suppl):S243–S249.
   PubMedGoogle Scholar
• Saloner B, Landis R, Stein BD, Barry CL. The Affordable Care Act in the heart of the opioid crisis: evidence from West Virginia. Health Aff (Millwood). 2019;38(4):633–642.
   PubMed Web of Science ®Google Scholar
• Peterson C, Xu L, Mikosz CA, Florence C, Mack KA. US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011–2015. J Subst Abuse Treat. 2018;92:35–39.
   PubMed Web of Science ®Google Scholar
• Peterson C, Xu L, Florence C, Mack KA. Opioid-related US hospital discharges by type, 1993–2016. J Subst Abuse Treat. 2019;103:9–13.
   PubMed Web of Science ®Google Scholar
• Cochran G, Gordon AJ, Lo-Ciganic WH, et al. An examination of claims-based predictors of overdose from a large medicaid program. Med Care. 2016; 55(3):291–298.
   Web of Science ®Google Scholar
• Kelty E, Hulse G. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Policy. 2017;46:54–60.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–394.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–170.
   PubMed Web of Science ®Google Scholar
• Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–157.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456–462.
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145.
   Google Scholar
• Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005;5:452–468.
   PubMedGoogle Scholar
• Giacomuzzi SM, Riemer Y, Ertl M, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98(5):693–702.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–642.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Margolis A, Heled L, Rosca P, Radomislensky I, Grinshpoon A. Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse. 2010;45(1–2):288–313.
   PubMed Web of Science ®Google Scholar
• Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019;2(6):e196373.
   PubMed Web of Science ®Google Scholar
• Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–482.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
   PubMed Web of Science ®Google Scholar
• Priest K. The COVID-19 Pandemic: practice and policy considerations for patients with opioid use disorder. Health Affairs Blog. 2020.
   Google Scholar
• Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020. doi:10.7326/M20-1212.
   PubMed Web of Science ®Google Scholar
• Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020. doi:10.7326/M20-1210.
   Web of Science ®Google Scholar
• NIDA. COVID-19: Potential implications for individuals with substance use disorders. https://www.drugabuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications-individuals-substance-use-disorders. Published 2020. Accessed April 6.
   Google Scholar
• Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020. doi:10.7326/M20-1141.
   PubMed Web of Science ®Google Scholar
• Cerda M, Vlahov D, Tracy M, Galea S. Alcohol use trajectories among adults in an urban area after a disaster: evidence from a population-based cohort study. Addiction. 2008;103(8):1296–1307.
   PubMed Web of Science ®Google Scholar
• Kotarba JA, Fackler J, Johnson BD, Dunlap E. The melding of drug markets in Houston after Katrina: dealer and user perspectives. Subst Use Misuse. 2010;45(9):1390–1405.
   PubMed Web of Science ®Google Scholar
• Shuler M, Suzuki S, Podesta A, Qualls-Hampton R, Wallington SF. A post-hurricane katrina examination of substance abuse treatment discharges with co-occurring psychiatric and substance use disorders. J Dual Diagn. 2017;13(2):144–156.
   PubMed Web of Science ®Google Scholar
• Shuler MN, Wallington SF, Qualls-Hampton RY, Podesta AE, Suzuki S. Trend analysis of substance abuse treatment admissions in new orleans from 2000–2012: a population-based comparison pre- and post-hurricane Katrina. Subst Use Misuse. 2016;51(12):1542–1554.
   PubMed Web of Science ®Google Scholar
• Phillippi SW, Beiter K, Thomas CL, et al. Medicaid utilization before and after a natural disaster in the 2016 Baton Rouge-area flood. Am J Public Health. 2019;109(S4):S316–S321.
   PubMedGoogle Scholar
• Dunlop A, Lokuge B, Masters D, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26.
   PubMed Web of Science ®Google Scholar
• Wilson CG, Ramage M, Fagan EB. A primary care response to COVID-19 for patients with an opioid use disorder. J Rural Health. 2020. doi:10.1111/jrh.12438.
   PubMed Web of Science ®Google Scholar
• Matusow H, Benoit E, Elliott L, Dunlap E, Rosenblum A. Challenges to opioid treatment programs after hurricane sandy: patient and provider perspectives on preparation, impact, and recovery. Subst Use Misuse. 2018;53(2):206–219.
   PubMed Web of Science ®Google Scholar
• Tofighi B, Grossman E, Goldfeld KS, Williams AR, Rotrosen J, Lee JD. Psychiatric comorbidity and substance use outcomes in an office-based buprenorphine program six months following hurricane Sandy. Subst Use Misuse. 2015;50(12):1571–1578.
   PubMed Web of Science ®Google Scholar
• McClure B, Mendoza S, Duncan L, Rotrosen J, Hansen H. Effects of regulation on methadone and buprenorphine provision in the wake of Hurricane Sandy. J Urban Health. 2014;91(5):999–1008.
   PubMed Web of Science ®Google Scholar
• Williams AR, Tofighi B, Rotrosen J, Lee JD, Grossman E. Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy. J Urban Health. 2014;91(2):366–375.
   PubMed Web of Science ®Google Scholar
• Tofighi B, Grossman E, Williams AR, Biary R, Rotrosen J, Lee JD. Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addict Sci Clin Pract. 2014;9:3
   PubMedGoogle Scholar
• Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. PLOS One. 2017;12(8):e0183172.
   PubMed Web of Science ®Google Scholar
• American Pharmacists Association. n.d. Pharmacists’ Impact on Patient Safety. Washington DC: American Pharmacists Association.
   Google Scholar
• Riffkin R. Americans rate nurses highest on honesty, ethical standards. Gallup. http://www.webcitation.org/6hZbvKPDQ. Published 2014. Accessed May 17, 2016.
   Google Scholar
• Khan NS, Norman IJ, Dhital R, McCrone P, Milligan P, Whittlesea CM. Alcohol brief intervention in community pharmacies: a feasibility study of outcomes and customer experiences. Int J Clin Pharm. 2013;35(6):1178–1187.
   PubMed Web of Science ®Google Scholar
• Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter R. Screening community pharmacy patients for risk of prescription opioid misuse. J Addict Med. 2015;9(5):411–416.
   PubMed Web of Science ®Google Scholar
• Cochran G, Chen Q, Field C, et al. A community pharmacy-led intervention for opioid medication misuse: a small-scale randomized clinical trial. Drug Alcohol Depend. 2019;205:107570.
   PubMed Web of Science ®Google Scholar
• Morton KJ, Harrand B, Floyd CC, et al. Pharmacy-based statewide naloxone distribution: a novel “top-down, bottom-up” approach. J Am Pharm Assoc (2003). 2017;57(2S):S99–S106.e105.
   PubMedGoogle Scholar
• Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21(2):187–210.
   PubMed Web of Science ®Google Scholar
• Chaar BB, Hanrahan JR, Day C. Provision of opioid substitution therapy services in Australian pharmacies. Australas Med J. 2011;4(4):210–216.
   PubMedGoogle Scholar
• Samet JH, Botticelli M. It’s time for methadone to be prescribed as part of primary care. https://www.statnews.com/2018/07/05/methadone-prescribed-primary-care/. Published 2018. Accessed April 30, 2020.
   Google Scholar
• Calcaterra SL, Bach P, Chadi A, et al. Methadone Matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–1042.
   PubMed Web of Science ®Google Scholar
• Methadone Maintenance Treatment Program Standards and Clinical Guidelines [press release]. Toronto: College of Physicians and Surgeons of Ontario; 2011.
   Google Scholar
• Berbatis CG, Sunderland VB, Joyce A, Bulsara M, Mills C. Enhanced pharmacy services, barriers and facilitators in Australia’s community pharmacies: Australia’s National Pharmacy Database Project. Int J Pharm Pract. 2007;15(3):185–191.
   Google Scholar
• NHS. Supervised Self Administration of Methadone and Buprenorphine Guidelines for Pharmacists and Pharmacy Technicians. Cumbria: National Health Service; 2010.
   Google Scholar
• Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract. 2005;55(515):444–451.
   PubMed Web of Science ®Google Scholar
• Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019;14(1):30–30.
   PubMed Web of Science ®Google Scholar
• Fischer B, Kurdyak P, Goldner E, Tyndall M, Rehm J. Treatment of prescription opioid disorders in Canada: looking at the ‘other epidemic’? Subst Abuse Treat Prev Policy. 2016;11(1):12.
   PubMedGoogle Scholar
• Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.
   PubMed Web of Science ®Google Scholar
• Austrailian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data Collection 2019. Sydney, Australia: Austrailian Institute of Health and Welfare; 2020.
   Google Scholar
• Havens JR, Walsh SL, Korthuis PT, Fiellin DA. Implementing treatment of opioid-use disorder in rural settings: a focus on HIV and hepatitis c prevention and treatment. Curr HIV/AIDS Rep. 2018;15(4):315–323.
   PubMed Web of Science ®Google Scholar
• Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
   PubMed Web of Science ®Google Scholar
• Eibl JK, Gomes T, Martins D, et al. Evaluating the effectiveness of first-time methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada. J Addict Med. 2015;9(6):440–446.
   PubMed Web of Science ®Google Scholar
• Insinger A. Methadone clinic lines and packed waiting rooms leave clients vulnerable to the coronavirus. In: STAT News; 2020. Boston.
   Google Scholar
• Levander X, Wakeman S. Covid-19 will worsen the opioid overdose crisis if we don’t prepare now. In: STAT News; 2020. Boston.
   Google Scholar
• Grierson J. Methadone to be supplied without new prescription during Covid-19 crisis. The Guardian. April 8, 2020.
   Google Scholar
• Clun R. Opioid addiction treatment must change during pandemic, experts say. The Sydney Morning Herald. April 24, 2020.
   Google Scholar
• Tait C, Gee M, Woo A. Pandemic restrictions reshape opioid treatment as doctors sound alarm. The Globe and Mail: Alberta. 2020.
   Google Scholar
• Controlled Drugs and Substances Act (CDSA), Subsection 56(1); Class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada during the coronavirus pandemic, §5; Subsection 56(1) 2020.
   Google Scholar
• Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139–144.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374–381.
   PubMed Web of Science ®Google Scholar
• Lagisetty P, Smith A, Antoku D, et al. A physician-pharmacist collaborative care model to prevent opioid misuse. Am J Health Syst Pharm. 2020;77(10):771–780.
   PubMed Web of Science ®Google Scholar
• Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu LT. Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature. Subst Abus. 2019;40(4):476–483. doi:10.1080/08897077.2019.1616349.
   PubMed Web of Science ®Google Scholar
• Ventricelli DJ, Mathis SM, Foster KN, Pack RP, Tudiver F, Hagemeier NE. Communication experiences of data-waivered physicians with community pharmacists: a qualitative study. Subst Use Misuse. 2020;55(3):349–357.
   PubMed Web of Science ®Google Scholar
• Yadav R, Taylor D, Taylor G, Scott J. Community pharmacists’ role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice. Int J Clin Pharm. 2019;41(2):470–477.
   PubMed Web of Science ®Google Scholar
• Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLOS One. 2017;12(10):e0186315
   PubMed Web of Science ®Google Scholar
• Matheson C, Thiruvothiyur M, Robertson H, Bond C. Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development. Int J Drug Policy. 2016;27:105–112.
   PubMed Web of Science ®Google Scholar
• Messaadi N, Pansu A, Cohen O, Cottencin O. Pharmacists’ role in the continued care of patients under opiate substitution treatment. Therapie. 2013;68(6):393–400.
   PubMed Web of Science ®Google Scholar
• Uosukainen H, Bell JS, Laitinen K, Tacke U, Ilomäki J, Turunen JHO. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland. Int J Drug Policy. 2013;24(5):492–497.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Clinical Investigators, Sponsors, and Irbs Investigational New Drug Applications (Inds) — Determining Whether Human Research Studies Can Be Conducted Without an IND. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration; 2015.
   Google Scholar
• Jun JK. The role of pharmacy through collaborative practice in an ambulatory care clinic. Am J Lifestyle Med. 2019;13(3):275–281.
   PubMed Web of Science ®Google Scholar
• Bach AT, Goad JA. The role of community pharmacy-based vaccination in the USA: current practice and future directions. Integr Pharm Res Pract. 2015;4:67–77.
   PubMed Web of Science ®Google Scholar
• Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12:25–25.
   PubMed Web of Science ®Google Scholar
• CDC. Collaborative Practice Agreements and Pharmacists’ Patient Care Services: A Resource for Pharmacists. Atlanta, GA: US Dept. of Health and Human Services, Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Jungnickel PW, Desimone EM, Kissack JC, AACP Special Committee on Substance Abuse and Pharmacy Education, et al. Report of the AACP special committee on substance abuse and pharmacy education. Am J Pharm Educ. 2010;74(10):S11.
   PubMedGoogle Scholar
• Tommasello AC. Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence. Harm Reduct J. 2004;1(1):3–3.
   PubMedGoogle Scholar
• Bratberg J. Pharmacy: Addressing substance use in the 21st century. Subst Abus. 2019;40(4):421–434.
   PubMed Web of Science ®Google Scholar
• Medscape. State CE Requirements for Pharmacists. https://www.medscape.org/public/pharmcestaterequirements. Published 2018. Accessed April 27, 2020.
   Google Scholar
• Goode J-V, Owen J, Page A, Gatewood S. Community-based pharmacy practice innovation and the role of the community-based pharmacist practitioner in the United States. Pharmacy. 2019;7(3):106.
   Web of Science ®Google Scholar
• Babar ZU, Scahill S, Nagaria RA, Curley LE. The future of pharmacy practice research - Perspectives of academics and practitioners from Australia, NZ, United Kingdom, Canada and USA. Res Social Adm Pharm. 2018;14(12):1163–1171.
   PubMed Web of Science ®Google Scholar
• Bacci JL, Berenbrok LA. Innovative advances in connectivity and community pharmacist patient care services: implications for patient safety. Pharmacotherapy. 2018;38(8):867–874.
   PubMed Web of Science ®Google Scholar
• Yap D. State provider status advances in 2017. Pharmacy Today. 2017;24:58.
   Google Scholar